Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

ICU Medical, Incorporated (ICUI): Has This Healthcare Device Innovator Put out the ‘For Sale’ Sign?

ICU Medical, Incorporated (NASDAQ:ICUI)ICU Medical, Incorporated (NASDAQ:ICUI)’s share price jumped sharply in early May after media outlets reported potential buyer interest in the medical device specialist. The company was one of the pioneers of needle-free connector devices that attach multiple syringes to a patient’s catheter, thereby allowing healthcare workers to avoid infection-causing needlepricks. Its Clave brand of devices has a leading market share in the IV connector segment, thanks to a cozy relationship with infusion therapy giant Hospira, Inc. (NYSE:HSP), and it has built an operating footprint across 50 countries. So, should investors take a position?

What’s the value?

As infections from needlepricks have grown alongside increased healthcare activity, the federal government has made healthcare worker safety a focal point. Congress passed the Needlestick Safety and Prevention Act in 2000, which required needle-safe systems at healthcare facilities and was a step up from the previous “universal precaution” standard. The Centers for Medicare and Medicaid Services brought out its own “stick” when it discontinued payments for hospital acquired infections caused by needlepricks in 2008. Both of these developments played into the hands of ICU Medical, Incorporated (NASDAQ:ICUI), whose products provide suitable protection against these accidental infections.

In the first six months of FY2013, ICU Medical, Incorporated (NASDAQ:ICUI) has posted somewhat weak results, with flat revenue growth and a 7.8% decline in operating income. Unit volume growth in the company’s core infusion device segment has flatlined and its newer forays into the critical care and oncology segments have posted mixed results. In addition, ICU Medical, Incorporated (NASDAQ:ICUI)’s profitability has been hit by the costs of maintaining a global sales force. However, the company has a $240 million cash position, and its leading market position likely holds value for a range of buyers.

Battle of the spinoffs

While ICU Medical, Incorporated (NASDAQ:ICUI)’s cash position would be enticing to financial buyers, the most likely acquirers are strategic buyers looking for synergies. At the top of the list is Hospira, Inc. (NYSE:HSP), the former Abbott Labs’ unit and a leader in infusion therapy and related pharmaceuticals. The company is ICU Medical, Incorporated (NASDAQ:ICUI)’s largest customer, accounting for over 40% of its total sales. The companies also have a relationship in the critical care segment, with a distribution agreement that runs through 2018.

In its latest fiscal year, Hospira, Inc. (NYSE:HSP) posted relatively weak financial results, due primarily to manufacturing problems with its Symbiq infusion pumps that led to a temporary halt of product sales in the fourth quarter of 2012. For the period, the company reported flat overall sales growth and a 43.2% drop in adjusted operating income. Hospira’s profitability was hurt by the lost sales, as well as higher quality assurance costs that were required as part of the FDA’s investigations of the company’s manufacturing practices.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.